Scandinavian Trial of Uncomplicated Aortic Dissection Therapy
Key facts
- Who runs it
- University of Aarhus
- Where
- Denmark, Finland, Iceland, Netherlands, Norway, and Sweden28 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Recruiting
- People taking part
- 554 people, planned
- Started
- 24 May 2023
- Expected to end
- 31 Dec 2030
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- TEVAR
- Record updated
- 11 August 2025
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 13 criteriaShow less
Who can take part
- All subjects, aged 18 or greater at the time of informed consent, admitted or referred to the participating vascular surgery site with an uTBAD of less than four weeks duration
Who cannot take part
- Subjects previously treated in their descending aorta, either open surgery or TEVAR
- Subjects with an established connective tissue disease at the time of randomization, including but not limited to Marfans and Loeys-Dietz syndrome
- Subjects with dementia
- Subjects with a clinically estimated life expectancy < 2 years
- Subjects with no signed informed consent
- Subjects presenting with a complicated type B aortic dissection according to the above definition
- Subjects with pre-existing thoracoabdominal aortic aneurysm
- Subjects with other aortic pathology with an indication for intervention that requires TEVAR
- Subjects with traumatic aortic dissections
- Pregnant or nursing subjects
- Subjects with current sepsis
- Subjects currently participating in other clinical interventional trials
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The introduction of thoracic endovascular aortic repair (TEVAR) in 1994 has radically changed the treatment of thoracic aortic pathology, and TEVAR is now the recommended therapy for "complicated" TBADs and other thoracic aorta diseases. To date, the use of TEVAR in the treatment of "uncomplicated" dissections (uTBAD) is uncertain, although it is presumed that a prophylactic procedure can prevent later complex surgery and early death. Several analyses have found that TEVAR confers improved aortic remodeling and possibly survival, although these were underpowered for this specific outcome. In addition, there are several reports regarding the uncertain benefit or harm of this intervention in the vascular surgery community. Put another way, there is equipoise, and the need for robust evidence in the form of a randomized clinical trial has been clearly iterated by the European Society of Vascular Surgery.
Read full original descriptionShow less
This randomized, open-label, two-armed controlled study directly addresses this question of whether TEVAR alters 5-year survival among patients with an uTBAD. Patients will be randomized to either standard medical therapy (SMT) alone or TEVAR in addition to SMT. The primary outcome is 5-year survival, while secondary outcomes include aortic-related mortality, neurological events, quality of life, costs, re interventions and readmissions. in addition, subgroup analyses based on the extent of treatment.
Sample size calculations based on previous reports indicate the need to include approximately 554 patients. Patients will be recruited from multiple centres in Scandinavia. Based on the population (24 million) and incidence of uTBAD (approximately 480 per year), and depending on the total number of participating centres, a conservative estimate of two to three years is required for enrolment.
The 2 groups in the trial
- Medical TherapyNo study treatment, for comparison
Patients will be treated with standard medical therapy, i.e., antihypertensives, pulse-rate regulators, and pain medication.
- Stent TherapyExisting treatment, for comparison
Patients will be treated with both standard medical therapy, in addition to placement of a thoracic endovascular aortic repair stent graft.
Treatment: TEVAR
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Publications
- Record updated
- 11 August 2025